{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:06:02Z","timestamp":1793066762714,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004901","name":"FAPEMIG","doi-asserted-by":"publisher","award":["APQ-01834-21"],"award-info":[{"award-number":["APQ-01834-21"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ijbiomac.2024.133283","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T13:28:46Z","timestamp":1718976526000},"page":"133283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P1","title":["Interaction of DisBa01 peptide from Bothrops alternatus venom with BRAF melanoma receptors: Modeling and molecular docking"],"prefix":"10.1016","volume":"274","author":[{"given":"Tatiane Senna","family":"Bialves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana Luiza","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Alexanders Amaya","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maur\u00edcio Nogueira","family":"Moys\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edleusa","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano Monteiro","family":"de Castro Pimenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Marques","family":"Quintela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego C\u00e9sar Batista","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederico Chaves","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel C.","family":"de Melo-Minardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Tew","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.ijbiomac.2024.133283_bb0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"148","author":"Luke","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0010","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3389\/fimmu.2019.00990","article-title":"Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma","volume":"10","author":"Yu","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0015","first-page":"3883","article-title":"BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma","volume":"63","author":"Dong","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0020","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nat. 4176892"},{"issue":"12","key":"10.1016\/j.ijbiomac.2024.133283_bb0025","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nm1469","article-title":"Tumor metastasis: mechanistic insights and clinical challenges","volume":"128","author":"Steeg","year":"2006","journal-title":"Nat. Med."},{"issue":"265","key":"10.1016\/j.ijbiomac.2024.133283_bb0030","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.7521539","article-title":"Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1","volume":"80","author":"Dameron","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0035","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1 \/ 2 MAP kinases: structure , function , and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0045","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nrm1834","article-title":"MAPKAP kinases - MKs - two\u2019s company, three\u2019s a crowd","volume":"7","author":"Gaestel","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0050","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/1947601911407323","article-title":"Raf family kinases: old dogs have learned new tricks","volume":"2","author":"Matallanas","year":"2011","journal-title":"Genes and Cancer."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035309","article-title":"Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials","volume":"7","author":"Lovly","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0060","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"Menzies","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0065","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/1535-7163.MCT-15-0617","article-title":"A novel RAF kinase inhibitor with DFG-out-binding mode: high efficacy in BRAF-mutant tumor xenograft models in the absence of normal tissue hyperproliferation","volume":"15","author":"Waizenegger","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0070","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nature14982","article-title":"RAF inhibitors that evade paradoxical MAPK pathway activation","volume":"526","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0075","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccell.2016.06.024","article-title":"An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling","volume":"30","author":"Karoulia","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0080","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/OTT.S39096","article-title":"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies","volume":"8","author":"Spagnolo","year":"2015","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0085","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0090","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with Vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0095","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3390\/ijms20061483","article-title":"Targeting the ERK signaling pathway in melanoma","volume":"20","author":"Savoia","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0100","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1158\/2159-8290.CD-17-1355","article-title":"ERK inhibition: a new front in the war against MAPK pathway\u2013driven cancers?","volume":"8","author":"Smalley","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0105","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.13005\/bpj\/2018","article-title":"In-silico analysis to determine the efficient drug for malignant melanoma using molecular dynamics","volume":"13","author":"Pallavi","year":"2020","journal-title":"Biomed. Pharmacol. J."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0110","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(20)30417-7","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"395","author":"Zimmer","year":"2020","journal-title":"Lancet"},{"issue":"73","key":"10.1016\/j.ijbiomac.2024.133283_bb0115","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s40265-013-0095-2","article-title":"Dabrafenib: first global approval","volume":"7312","author":"Ballantyne","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0120","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0125","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600\u2013mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0130","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/01.HYP.17.4.589","article-title":"History of the design of captopril and related inhibitors of angiotensin converting enzyme","volume":"17","author":"Cushman","year":"1991","journal-title":"Hypertension"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0135","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.toxicon.2014.10.020","article-title":"Toxins and drug discovery","volume":"92","author":"Harvey","year":"2014","journal-title":"Toxicon"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0140","first-page":"1","article-title":"Snake venom toxins: clinical use and as diagnostic agents","volume":"8","author":"Kumar","year":"2021","journal-title":"Shanlax Int. J. Arts, Sci. Humanit."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0145","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41570-022-00393-7","article-title":"The chemistry of snake venom and its medicinal potential","volume":"6","author":"Oliveira","year":"2022","journal-title":"Nat. Rev. Chem."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0150","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0033-0620(78)90024-5","article-title":"Captopril (SQ 14,225) (d-3-mercapto-2-methylpropanoyl-l-proline): a novel orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent","volume":"21","author":"Rubin","year":"1978","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0155","first-page":"600","article-title":"Macrovipecetin, a C-type lectin from Macrovipera lebetina venom, inhibits proliferation migration and invasion of SK-MEL-28 human melanoma cells and enhances their sensitivity to cisplatin","volume":"2018","author":"Hammouda","year":"1862","journal-title":"Biochim. Biophys. Acta - Gen. Subj."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0160","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijbiomac.2016.07.022","article-title":"Mechanism of the cytotoxic effect of L-amino acid oxidase isolated from Bothrops alternatus snake venom","volume":"92","author":"Ribeiro","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3181\/00379727-195-43129B","article-title":"Disintegrins: a family of lntegrin inhibitory","volume":"195","author":"Gould","year":"1990","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0170","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1042\/bj20021739","article-title":"Snake venom disintegrins: novel dimeric disintegrins and structural diversification by disulphide bond engineering","volume":"372","author":"Calvete","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0175","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.V90.4.1565","article-title":"Significance of RGD loop and C-terminal domain of echistatin for recognition of \u03b1IIb\u03b23 and \u03b1v\u03b23 Integrins and expression of ligand-induced binding site","volume":"90","author":"Marcinkiewicz","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10080321","article-title":"Recombinant and chimeric disintegrins in preclinical research","volume":"10","author":"David","year":"2018","journal-title":"Toxins (Basel)."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/biom11081213","article-title":"Cell adhesion molecules in normal skin and melanoma","volume":"11","author":"D\u2019arcy","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0190","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3390\/ijms23031745","article-title":"The effects of \u03b1v\u03b23 integrin blockage in breast tumor and endothelial cells under hypoxia in vitro","volume":"23","author":"Casali","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0195","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.biochi.2012.04.020","article-title":"Blocking \u03b1v\u03b23 integrin by a recombinant RGD disintegrin impairs VEGF signaling in endothelial cells","volume":"94","author":"Montenegro","year":"2012","journal-title":"Biochimie"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0200","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10585-007-9101-y","article-title":"A novel \u03b1v\u03b23-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis","volume":"25","author":"Ramos","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0205","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0046-8177(99)90202-2","article-title":"Progression-related expression of \u03b23 integrin in melanomas and nevi","volume":"30","author":"Van Belle","year":"1999","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0210","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1172\/JCI115811","article-title":"Involvement of integrin alpha V gene expression in human melanoma tumorigenicity","volume":"89","author":"Felding-Habermann","year":"1992","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0215","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-019-0339-1","article-title":"Recombinant RGD-disintegrin DisBa-01 blocks integrin \u03b1 v \u03b2 3 and impairs VEGF signaling in endothelial cells","volume":"17","author":"Danilucci","year":"2019","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.123367","article-title":"Snake venom, a potential treatment for melanoma. A systematic review","volume":"231","author":"Bialves","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0225","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab160","article-title":"DeepImmuno: deep learning-empowered prediction and generation of immunogenic peptides for T-cell immunity","volume":"22","author":"Li","year":"2021","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2023.108564","article-title":"Bambu and its applications in the discovery of active molecules against melanoma","volume":"124","author":"Guidotti","year":"2023","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.simpa.2024.100623","article-title":"Caramel: a web-based QSAR tool for melanoma drug discovery","volume":"19","author":"Guidotti","year":"2024","journal-title":"Softw. Impacts."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0240","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/0261192920965977","article-title":"A review of in silico tools as alternatives to animal testing: principles, resources and applications","volume":"48","author":"Madden","year":"2020","journal-title":"ATLA Altern. to Lab. Anim."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0245","doi-asserted-by":"crossref","first-page":"305","DOI":"10.32604\/or.2022.025187","article-title":"Computational high-throughput screening and in vitro approaches identify CB-006-3; a novel PI3K-BRAFV600E dual targeted inhibitor against melanoma","volume":"29","author":"Tobeigei","year":"2021","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0250","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cels.2018.06.002","article-title":"Dissecting RAF inhibitor resistance by structure-based modeling reveals ways to overcome oncogenic RAS signaling","volume":"7","author":"Rukhlenko","year":"2018","journal-title":"Cell Syst."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0255","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s11864-022-01006-7","article-title":"BRAF inhibitor resistance in melanoma: mechanisms and alternative therapeutic strategies","volume":"23","author":"Chen","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/atm.2016.06.07","article-title":"Resistant mechanisms to BRAF inhibitors in melanoma","volume":"4","author":"Manzano","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0265","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0270","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","article-title":"ColabFold: making protein folding accessible to all","volume":"19","author":"Mirdita","year":"2022","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0275","doi-asserted-by":"crossref","first-page":"W365","DOI":"10.1093\/nar\/gkx407","article-title":"HDOCK: a web server for protein\u2013protein and protein\u2013DNA\/RNA docking based on a hybrid strategy","volume":"45","author":"Yan","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0280","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2004.09.022","article-title":"Guilty as charged: B-RAF is a human oncogene","volume":"6","author":"Garnett","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0285","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkq929","article-title":"COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer","volume":"39","author":"Forbes","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0290","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0295","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1093\/emboj\/20.14.3716","article-title":"Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601","volume":"20","author":"Chong","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0300","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.0711741105","article-title":"From the cover: discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity","volume":"105","author":"Tsai","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0305","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nsmb.2924","article-title":"Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation","volume":"22","author":"Thevakumaran","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0310","series-title":"VTR: An Algorithm for Identifying Analogous Contacts on Protein Structures and Their Complexes","author":"Pimentel","year":"2020"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0315","first-page":"28","article-title":"VTR: a web tool for identifying analogous contacts on protein structures and their complexes","volume":"0","author":"Pimentel","year":"2021","journal-title":"Front. Bioinforma."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0320","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1093\/bioinformatics\/btw514","article-title":"PRODIGY: a web server for predicting the binding affinity of protein\u2013protein complexes","volume":"32","author":"Xue","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0325","first-page":"1","article-title":"The star STING server: a multiplatform environment for protein structure analysis","volume":"5","author":"Neshich","year":"2007","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0330","doi-asserted-by":"crossref","first-page":"W233","DOI":"10.1093\/nar\/gkn216","article-title":"The RosettaDock server for local protein\u2013protein docking","volume":"36","author":"Lyskov","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0335","doi-asserted-by":"crossref","first-page":"W338","DOI":"10.1093\/nar\/gky356","article-title":"CABS-flex 2.0: a web server for fast simulations of flexibility of protein structures","volume":"46","author":"Kuriata","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0340","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107207118","article-title":"Allosteric MEK inhibitors act on BRAF\/MEK complexes to block MEK activation","volume":"118","author":"Gonzalez-Del Pino","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"10.1016\/j.ijbiomac.2024.133283_bb0345","first-page":"1","article-title":"Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding","volume":"131","author":"Martinez Fiesco","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0350","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature08314","article-title":"A dimerization-dependent mechanism drives RAF catalytic activation","volume":"461","author":"Rajakulendran","year":"2009","journal-title":"Nat. 4617263"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0355","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1093\/emboj\/19.20.5429","article-title":"Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601","volume":"19","author":"Zhang","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0360","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0022-2836(03)00991-4","article-title":"Crystal structure of trimestatin, a disintegrin containing a cell adhesion recognition motif RGD","volume":"332","author":"Fujii","year":"2003","journal-title":"J. Mol. Biol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.133283_bb0365","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nrd1549","article-title":"Docking and scoring in virtual screening for drug discovery: methods and applications","volume":"311","author":"Kitchen","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2013.07.046","article-title":"XAllosteric activation of functionally asymmetric RAF kinase dimers","volume":"154","author":"Hu","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0375","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1021\/bi701350v","article-title":"Conformational switching upon phosphorylation: a predictive framework based on energy landscape principles","volume":"47","author":"L\u00e4tzer","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/toxins8070206","article-title":"Lebein, a snake venom disintegrin, induces apoptosis in human melanoma cells","volume":"8","author":"Hammouda","year":"2016","journal-title":"Toxins (Basel)."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0385","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.matbio.2013.01.001","article-title":"Inhibition of integrins \u03b1v\/\u03b15-dependent functions in melanoma cells by an ECD-disintegrin acurhagin-C","volume":"32","author":"Shih","year":"2013","journal-title":"Matrix Biol."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0390","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1517\/13543784.2011.602064","article-title":"Crotamine toxicity and efficacy in mouse models of melanoma","volume":"20","author":"Pereira","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0395","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00726-017-2513-3","article-title":"Oral treatment with a rattlesnake native polypeptide crotamine efficiently inhibits the tumor growth with no potential toxicity for the host animal and with suggestive positive effects on animal metabolic profile","volume":"50","author":"Campeiro","year":"2018","journal-title":"Amino Acids"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0400","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00210-021-02103-4","article-title":"Acute toxicity, antinociceptive, and anti-inflammatory activities of the orally administered crotamine in mice, Naunyn. Schmiedebergs","volume":"394","author":"Moreira","year":"2021","journal-title":"Arch. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0405","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.toxicon.2014.02.018","article-title":"A lectin from Bothrops leucurus snake venom raises cytosolic calcium levels and promotes B16-F10 melanoma necrotic cell death via mitochondrial permeability transition","volume":"82","author":"Aranda-Souza","year":"2014","journal-title":"Toxicon"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0410","series-title":"Vemurafenib, Recent Results Cancer Res","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-3-319-91442-8_6","author":"Garbe","year":"2018"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0415","series-title":"Biologia molecular da c\u00e9lula","author":"Alberts","year":"2017"},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0420","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1021\/jm300126x","article-title":"Design and synthesis of novel DFG-Out RAF\/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds","volume":"55","author":"Okaniwa","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2024.133283_bb0425","doi-asserted-by":"crossref","first-page":"9496","DOI":"10.1002\/anie.201102971","article-title":"Increasing \u03b1v\u03b23 selectivity of the anti-angiogenic drug cilengitide by N-methylation","volume":"50","author":"Mas-Moruno","year":"2011","journal-title":"Angew. Chemie - Int. Ed."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024040881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024040881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T20:32:37Z","timestamp":1782765157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813024040881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":85,"alternative-id":["S0141813024040881"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.133283","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interaction of DisBa01 peptide from Bothrops alternatus venom with BRAF melanoma receptors: Modeling and molecular docking","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.133283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"133283"}}